UBS maintained a Buy rating on Alexion Pharmaceuticals (NASDAQ: ALXN), and cut the price target to $200.00 (from $222.00), following ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE